<DOC>
	<DOCNO>NCT01815528</DOCNO>
	<brief_summary>Single -arm , multicenter phase-II trial catumaxomab chemotherapy patient recurrent ovarian cancer investigate feasibility clinical activity initial intraperitoneal catumaxomab follow chemotherapy regime .</brief_summary>
	<brief_title>Feasibility Clinical Activity Initial Intraperitoneal Catumaxomab Followed Chemotherapy Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Histologically cytologically confirm epithelial ovarian cancer , primary peritoneal carcinomatosis fallopian tube cancer Recurrent ovarian cancer disease Signs progression either measurable disease accord RECIST CA 125 increase accord GCIGcriteria clinical symptom tumor progression accord RECIST Radiologically cytologically confirm malignant ascites possible puncture Life expectancy ≥ 12 week Age ≥ 18 year ECOG performance status least 1 No prior operation , case prior operation , patient must recover therefrom . The operation must perform least 4 week prior start study drug Capable understanding purpose risk study , willing able participate study , write informed consent Nonchildbearing potential negative pregnancy test know brain metastasis Concomitant cancer , chemo radiotherapy ( except local radiation therapy bone marrow metastasis ) Any investigational product within 2 week prior first administration catumaxomab In case previous exposure investigational product , cancer , chemo , immune radiotherapy ( except local radiation therapy bone marrow metastasis ) : sufficiently recover previous treatment ( toxicity present ) base adequate laboratory value general status accord in/exclusion criterion ( i.e . might less 1 2 week weekly biweekly schedule previous therapy regimen ) Patients must expose nitrosoureas mitomycin C within 6 week prior first infusion catumaxomab Abnormal organ bone marrow function Use immunesuppressive agent past 4 week prior first administration catumaxomab . For regular use systemic corticosteroid patient include stepwise discontinuation free steroid minimum 5 day prior study entry Any known active chronic infection Known HIV infection / hepatitis B virus hepatitis C virus Any concurrent disease medical condition deem interfere conduct study judge investigator Known suspect hypersensitivity catumaxomab analogues general murine protein ( rat mouse ) Known suspect hypersensitivity PLD , topotecan , paclitaxel , gemcitabine excipients . Patients congestive heart failure New York Heart Association ( NYHA ) Class III IV . Cardiac arrhythmia ( except atrioventricular block type I II , atrial fibrillation/flutter bundle brunch block ) sign symptom relevant cardiovascular disease Body mass index ( BMI ) &lt; 17 ( assessment ascites drainage ) Inadequate respiratory function opinion investigator Presence complete bowel obstruction Patients substance abuse , medical psychological social condition investigator believe would preclude compliance study requirement . Unwilling unable follow protocol requirement Participation another clinical study experimental therapy within 14 day start treatment Legal incapacity limit legal capacity Subjects house institution official legal order Pregnancy lactation period</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>recurrent epithelial ovarian cancer</keyword>
</DOC>